Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances

被引:4
作者
Minnema, Jordi [1 ]
Borgos, Sven Even F. [2 ]
Liptrott, Neill [3 ]
Vandebriel, Rob [1 ]
Delmaar, Christiaan [1 ]
机构
[1] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands
[2] SINTEF, Trondheim, Norway
[3] Univ Liverpool, Immunocompatibil Grp, Dept Pharmacol & Therapeut, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England
关键词
Physiologically based pharmacokinetic modeling; Nanobiomaterials (NBMs); Biodistribution; Bayesian parameter estimation; IN-VIVO BIODISTRIBUTION;
D O I
10.1007/s13346-022-01159-w
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
The use of nanobiomaterials (NBMs) is becoming increasingly popular in the field of medicine. To improve the understanding on the biodistribution of NBMs, the present study aimed to implement and parametrize a physiologically based pharmacokinetic (PBPK) model. This model was used to describe the biodistribution of two NBMs after intravenous administration in rats, namely, poly(alkyl cyanoacrylate) (PACA) loaded with cabazitaxel (PACA-Cbz), and Liplmage (TM) 815. A Bayesian parameter estimation approach was applied to parametrize the PBPK model using the biodistribution data. Parametrization was performed for two distinct dose groups of PACA-Cbz. Furthermore, parametrizations were performed three distinct dose groups of Liplmage (TM) 815, resulting in a total of five different parametrizations. The results of this study indicate that the PBPK model can be adequately parametrized using biodistribution data. The PBPK parameters estimated for PACA-Cbz, specifically the vascular permeability, the partition coefficient, and the renal clearance rate, substantially differed from those of Liplmage (TM) 815. This emphasizes the presence of kinetic differences between the different formulations and substances and the need of tailoring the parametrization of PBPK models to the NBMs of interest. The kinetic parameters estimated in this study may help to establish a foundation for a more comprehensive database on NBM-specific kinetic information, which is a first, necessary step towards predictive biodistribution modeling. This effort should be supported by the development of robust in vitro methods to quantify kinetic parameters.
引用
收藏
页码:2132 / 2144
页数:13
相关论文
共 50 条
[21]   Integrating a Microphysiological System and Physiologically Based Pharmacokinetic Modeling to Predict Human Responses to Diclofenac [J].
Choi, Suein ;
Lee, Junghyun ;
Kim, Okju ;
Jung, Yushin ;
Ryu, Taehoon ;
Kim, Su Jung ;
Kim, Eun Joo ;
Sung, Jong Hwan ;
Cha, Hwa Jun ;
Han, Sungpil .
BIOCHIP JOURNAL, 2025, 19 (02) :350-366
[22]   Use of Physiologically Based Pharmacokinetic Modeling for Hepatically Cleared Drugs in Pregnancy: Regulatory Perspective [J].
Coppola, Paola ;
Kerwash, Essam ;
Cole, Susan .
JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 :S62-S80
[23]   Establishing Clinically Relevant Specifications for Carbamazepine Tablets Using Physiologically Based Pharmacokinetic Modeling [J].
Wang, Xiaofeng ;
Li, Longjie ;
Yang, Hongyi ;
He, Qingfeng ;
Zhu, Xiao ;
Wang, Jiajing ;
Sun, Bo ;
Liu, Peng ;
Xiang, Xiaoqiang .
AAPS JOURNAL, 2025, 27 (04)
[24]   Whole-Body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics [J].
Bae, Dong-Jun ;
Kim, Sang-Yeob ;
Bae, Sang Mun ;
Hwang, Ae-Kyung ;
Pak, Kwan Cheol ;
Yoon, SeokKyu ;
Lim, Hyeong-Seok .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (06) :2180-2190
[25]   Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation [J].
Aborig, Mohamed ;
Malik, Paul R. V. ;
Nambiar, Shruti ;
Chelle, Pierre ;
Darko, Johnson ;
Mutsaers, Anthony ;
Edginton, Andrea N. ;
Fleck, Andre ;
Osei, Ernest ;
Wettig, Shawn .
PHARMACEUTICS, 2019, 11 (04)
[26]   Whole-Body Physiologically Based Pharmacokinetic Modeling of GalNAc-Conjugated siRNAs [J].
Salim, Emilie Langeskov ;
Kristensen, Kim ;
Sjogren, Erik .
PHARMACEUTICS, 2025, 17 (01)
[27]   Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles [J].
Liang, Xiaowen ;
Wang, Haolu ;
Grice, Jeffrey E. ;
Li, Li ;
Liu, Xin ;
Xu, Zhi Ping ;
Roberts, Michael S. .
NANO LETTERS, 2016, 16 (02) :939-945
[28]   Similarities and Differences in Gastrointestinal Physiology Between Neonates and Adults: a Physiologically Based Pharmacokinetic Modeling Perspective [J].
Guo Yu ;
Qing-Shan Zheng ;
Guo-Fu Li .
The AAPS Journal, 2014, 16 :1162-1166
[29]   CMATRIX - SOFTWARE FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING USING A SYMBOLIC MATRIX REPRESENTATION SYSTEM [J].
BALL, R ;
SCHWARTZ, SL .
COMPUTERS IN BIOLOGY AND MEDICINE, 1994, 24 (04) :269-276
[30]   Physiologically Based Pharmacokinetic Modeling of Deltamethrin: Development of a Rat and Human Diffusion-Limited Model [J].
Godin, Stephen J. ;
DeVito, Michael J. ;
Hughes, Michael F. ;
Ross, David G. ;
Scollon, Edward J. ;
Starr, James M. ;
Setzer, R. Woodrow ;
Conolly, Rory B. ;
Tornero-Velez, Rogelio .
TOXICOLOGICAL SCIENCES, 2010, 115 (02) :330-343